← Human Trials & Peer-Reviewed Studies
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Plain-language guide to PMID 9005976 (1997): clinical trial study of GHRH (Growth Hormone-Releasing Hormone) and Sermorelin.
Key Facts
- PMID
- 9005976
- Journal
- Metabolism: clinical and experimental
- Year
- 1997
- Study type
- Clinical Trial
- Authors
- Vittone J et al. (13 authors)
- DOI
- 10.1016/s0026-0495(97)90174-8
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of GHRH (Growth Hormone-Releasing Hormone) and Sermorelin, published as a clinical trial.
The relationship of this phenomenon to skeletal muscle bioenergetics has not been reported.
The researchers measured GH secretion, muscle strength, muscle histology, and muscle energy metabolism by phosphorus nuclear magnetic resonance spectroscopy (31P-NMRS), body composition, and endocrine-metabolic functions before and after 6 weeks of treatment.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, men only.
How the Study Was Run
The methods mention a period of 6 weeks.
What Was Measured
The researchers measured GH secretion, muscle strength, muscle histology, and muscle energy metabolism by phosphorus nuclear magnetic resonance spectroscopy (31P-NMRS), body composition, and endocrine-metabolic functions before and after 6 weeks of treatment.
The researchers measured GH levels in blood samples obtained every 20 minutes from 8:00 PM to 8:00 AM; AM serum levels of IGF-I, IGF binding protein-3 (IGFBP-3), and GH binding protein (GHBP); muscle strength; muscle histology; the normalized phosphocreatine abundance, PCr/[PCr + Pi], and intracellular pH in forearm muscle by NMRS during both sustained and ramped exercise; body composition by dual-energy x-ray absorptiometry (DEXA); lipid levels; and glucose, insulin, and GH levels during an oral glucose tolerance test (OGTT).
Topics PubMed links to this paper include Aging, Blood Glucose, Blood Pressure, Body Composition, Body Mass Index, Endocrine Glands and Energy Metabolism.
What This Means in Plain Language
This is a clinical trial of GHRH (Growth Hormone-Releasing Hormone) and Sermorelin over 6 weeks.
The publication is from 1997 (Metabolism: clinical and experimental), a journal based in United States.
More context: the GHRH (Growth Hormone-Releasing Hormone) compound page and the Sermorelin compound page, all human trials.
Our Notes on the Compounds
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Sermorelin: The first 29 amino acids of growth hormone-releasing hormone; once FDA-approved (Geref) and now mainly compounded.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.